Integrin Inhibitors as a Therapeutic Agent for Ovarian Cancer

Integrin Inhibitors as a Therapeutic Agent for Ovarian Cancer

Ovarian cancer is a deadly disease, with a cure rate of only 30%. Despite aggressive treatments, relapse remains almost inevitable in patients with advanced-stage disease. In recent years, great progress has been made towards targeting integrins in cancer treatment, and clinical studies with various...

Full description

Bibliographic Details
Main Authors:	Kenjiro Sawada, Chifumi Ohyagi-Hara, Tadashi Kimura, Ken-ichirou Morishige
Format:	Article
Language:	English
Published:	Hindawi Limited 2012-01-01
Series:	Journal of Oncology
Online Access:	http://dx.doi.org/10.1155/2012/915140

Similar Items

Potential of Integrin Inhibitors for Treating Ovarian Cancer: A Literature Review
by: Masaki Kobayashi, et al.
Published: (2017-07-01)

Interleukin 6 receptor is an independent prognostic factor and a potential therapeutic target of ovarian cancer.
by: Aki Isobe, et al.
Published: (2015-01-01)

Pathophysiological Role and Potential Therapeutic Exploitation of Exosomes in Ovarian Cancer
by: Aasa Shimizu, et al.
Published: (2020-03-01)

The Role of MicroRNAs in Ovarian Cancer
by: Yasuto Kinose, et al.
Published: (2014-01-01)

Role of the Exosome in Ovarian Cancer Progression and Its Potential as a Therapeutic Target
by: Koji Nakamura, et al.
Published: (2019-08-01)

Integrin-Linked Kinase Is a Novel Therapeutic Target in Ovarian Cancer
by: Michael A. Ulm, et al.
Published: (2020-11-01)

Therapeutic applications of PARP inhibitors in ovarian cancer
by: Hongyu Xie, et al.
Published: (2020-07-01)

Integrin Inhibitors in Prostate Cancer
by: Maylein C. Juan-Rivera, et al.
Published: (2018-02-01)

Pure Primary Ovarian Squamous Cell Carcinoma Perforating the Rectum
by: Kazuya Mimura, et al.
Published: (2017-01-01)

Integrins as Therapeutic Targets: Successes and Cancers
by: Sabine Raab-Westphal, et al.
Published: (2017-08-01)

Integrins as attractive targets for cancer therapeutics
by: Meng Li, et al.
Published: (2021-09-01)

High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the “SET” feature of high-grade serous carcinoma to the “STEM” feature
by: Yuichiro Hatano, et al.
Published: (2019-01-01)

Andrographolide as a therapeutic agent against breast and ovarian cancers
by: Beesetti Swarna Latha, et al.
Published: (2019-12-01)

Integrin Targeted Therapeutics
by: Melissa Millard, Srinivas Odde, Nouri Neamati
Published: (2011-01-01)

Preclinical therapeutic potential of a nitrosylating agent in the treatment of ovarian cancer.
by: Shailendra Giri, et al.
Published: (2014-01-01)

Therapeutic targeting of Integrin v 6 in breast cancer
by: Moore, K.M, et al.
Published: (2014)

Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer
by: Sarah J Taylor, et al.
Published: (2020-02-01)

Integrated Analysis of Prognostic and Immune Associated Integrin Family in Ovarian Cancer
by: Anqi Wu, et al.
Published: (2020-07-01)

Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells
by: Francesca Roggiani, et al.
Published: (2016-08-01)

The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer
by: Dineo eKhabele
Published: (2014-05-01)

Extracellular matrix interactions in ovarian cancer : an investigation into the role of integrins and matrix metalloproteinases in ovarian tumour progression
by: Afzal, Saliha
Published: (1998)

β1 integrins as therapeutic targets to disrupt hallmarks of cancer
by: Anne-Florence eBlandin, et al.
Published: (2015-11-01)

High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
by: Yuichiro Hatano, et al.
Published: (2018-04-01)

Kinase Inhibitors and Ovarian Cancer
by: Periklis Katopodis, et al.
Published: (2019-09-01)

Integrins and Cadherins as Therapeutic Targets in Fibrosis
by: Sandeep Krishna Agarwal
Published: (2014-06-01)

Integrin Targeted Delivery of Gene Therapeutics
by: Rudy L Juliano, Xin Ming, Osamu Nakagawa, Rongzuo Xu, Hoon Yoo
Published: (2011-01-01)

Antimetastatic Integrin as Inhibitors of Snake Venoms
by: Felix Rosenow, et al.
Published: (2008-02-01)

Platinum-based DNA binding agents as telomerase inhibitors and cancer therapeutics
by: Kieltyka, Roxanne
Published: (2009)

Small Molecule Inhibitors of Stat3 Protein as Cancer Therapeutic Agents
by: Page, Brent
Published: (2013)

Small Molecule Inhibitors of Stat3 Protein as Cancer Therapeutic Agents
by: Page, Brent
Published: (2013)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
by: Man Yee T. Keung, et al.
Published: (2019-03-01)

Neutrophil integrins as alternative targets for the therapeutic benefits of Î±_I_I_bÎ²â‚ƒ inhibitors
by: Aylott, Caroline Victoria
Published: (2004)

Investigating the Therapeutic Efficacy of a Novel Inhibitor GAP-107B8 on Ovarian Cancer Cells
by: Yan, Fu J
Published: (2011)

Investigating the Therapeutic Efficacy of a Novel Inhibitor GAP-107B8 on Ovarian Cancer Cells
by: Yan, Fu J
Published: (2011)

Investigating the Therapeutic Efficacy of a Novel Inhibitor GAP-107B8 on Ovarian Cancer Cells
by: Yan, Fu J
Published: (2011)

Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer.
by: Shailendra Giri, et al.
Published: (2013-01-01)

Development of Therapeutic Vaccines for Ovarian Cancer
by: Stephanie Chow, et al.
Published: (2020-11-01)

Therapeutic strategies in epithelial ovarian cancer
by: Kim Ayako, et al.
Published: (2012-02-01)

Scope of nanotechnology in ovarian cancer therapeutics
by: Yallapu Murali M, et al.
Published: (2010-08-01)

Wnt5A modulates integrin expression in a receptor-dependent manner in ovarian cancer cells
by: Vajihe Azimian-Zavareh, et al.
Published: (2021-03-01)

Cannot write session to /tmp/vufind_sessions/sess_g0gdrdoj8i26f8dp55kev3kf4g